Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide + ADT Adjuvant After Radical Prostatectomy in High-risk Prostate Cancer
NCT07282197Phase 2Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jan 2026
- Primary completion
- Mar 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of darolutamide in prostate cancer (PCa), sponsored by Peking University First Hospital. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07282197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07282197.